United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
PHILADELPHIA, Jan. 26, 2016 -- Medgenics, Inc. (NYSE MKT:MDGN), today announced that members of its management team will participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day on Tuesday, February 2, 2016 in New York, NY.
About Medgenics, Inc.
Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. For more information, visit the Company's website at www.medgenics.com.
Contacts: Medgenics, Inc. Brian Piper [email protected]
